Market Overview
According to Fortune Business Insights, the global chronic kidney disease market size was valued at USD 90.41 billion in 2025. The market is projected to grow from USD 96.33 billion in 2026 to USD 160.02 billion by 2034, exhibiting a CAGR of 6.55% during the forecast period. North America dominated the chronic kidney disease market in 2025.
Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Chronic Kidney Disease Market, 2026-2034.”
The analysis shows that the market is witnessing significant growth due to the increasing incidence of chronic kidney disease (CKD), alongside rising rates of diabetes, high blood pressure, and diagnostics globally. For example, according to data published by The Professional Society for Health Economics and Outcomes Research (ISPOR) in 2023, an estimated 3.25 million adults in the U.K. are suffering from chronic kidney disease. This trend, coupled with a growing number of drug candidates in the pipeline, indicates a strong demand for CKD treatments worldwide.
Major Players Profiled in the Market Report:
- GlaxoSmithKline plc. (U.K.)
- Sanofi (France)
- AstraZeneca (U.K.)
- Amgen Inc. (U.S.)
- Kissei Pharmaceutical Co., Ltd (Japan)
- Johnson & Johnson Services, Inc. (U.S.)
- Hoffmann-La Roche AG (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
Segments
Widespread Use as a First-Line Treatment to Propel ACE Inhibitors Segment Growth
Based on drug class, the market is divided into ACE inhibitors, angiotensin-II receptor blockers, calcium channel blockers, beta-blockers, erythropoiesis-stimulating agents (ESAs), diuretics, and others. The ACE inhibitors segment accounts for a significant revenue share and dominates the market owing to its widespread use as a first-line treatment for CKD—particularly in patients with hypertension and diabetic nephropathy—to reduce blood pressure, lower proteinuria, and prevent end-stage renal disease.
High Convenience and Self-Administration to Drive Oral Segment Expansion
By route of administration, the market is categorized into oral and parenteral. The oral segment is leading the market as there is a high preference for oral medications due to their convenience, increasing demand for self-administration options among patients, and frequent new product launches, such as Zydus Lifesciences' oral medication, Oxemia.
Hospital Pharmacies to Dominate the Market Due to Rising Hospital Diagnoses
Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment holds a significant market share owing to patient convenience, the easy availability of drugs, and the growing number of global CKD cases that require hospitalization and initial diagnosis in hospital settings.
Geographically, the market is studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
For detailed market insights: https://www.fortunebusinessinsights.com/chronic-kidney-disease-market-111644
Report Coverage
The report offers:
- Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
- Comprehensive insights into regional developments.
- List of major industry players.
- Key strategies adopted by the market players.
- The latest industry developments include product launches, partnerships, mergers, and acquisitions.
Drivers & Restraints
Increasing Prevalence of Chronic Kidney Diseases to Propel Market Growth
The rapid growth in the prevalence of CKD globally—affecting more than 10% of the worldwide population (over 800 million individuals)—is a primary driver boosting market growth. Key factors contributing to this rise include diabetes-related nephropathy, hypertension-induced renal diseases, an aging population, and increased awareness regarding early diagnosis. For instance, a May 2024 CDC report noted that about 14% of adults in the U.S. (roughly 35.5 million individuals) have CKD, driving the demand for effective drugs.
However, factors restricting patient adherence to medication may hamper market growth. Managing a high number of drugs for associated chronic conditions, high medication costs in low-income countries, and common drug side effects—such as hyperkalemia (elevated potassium levels) from ACE inhibitors—can limit adoption and market expansion.
Regional Insights
High Disease Prevalence and Strong Drug Adoption in the U.S. Propels Market Growth in North America
North America is projected to lead the global chronic kidney disease market share throughout the forecast period. The region’s growth is attributed to a high prevalence of CKD (affecting more than 1 in 7 U.S. adults), the strong presence of major pharmaceutical companies, high adoption rates of advanced drugs, and increased awareness regarding diagnosis. Europe is anticipated to hold the second-largest share due to growing demand for innovative therapies.
Asia Pacific is experiencing rapid growth in the market. The growth is attributed to rising awareness and increasing incidence rates in developing nations, with estimates showing China and India having 159.8 million and 140.2 million adults affected by CKD, respectively. Meanwhile, Latin America and the Middle East & Africa are anticipated to see stimulated growth due to improving awareness and increased healthcare spending.
Chronic Kidney Disease Market Future Growth:
The chronic kidney disease market is experiencing robust growth, fueled by an aging global population, rising rates of diabetes and hypertension, and the emergence of novel pipeline therapeutics aimed at improving patient outcomes. Today's healthcare landscape is increasingly drawn to innovative treatment options, with recent advancements in therapies such as SGLT2 inhibitors and GLP-1 receptor agonists showing immense promise in managing diabetes and slowing the progression of kidney damage. Additionally, ongoing R&D initiatives and expanding clinical pipelines are expected to unlock new market opportunities. While North America and Europe continue to dominate due to advanced healthcare infrastructure and therapy adoption, the Asia-Pacific region is seeing a rapid surge in demand driven by massive patient pools and improving diagnostic awareness.
Competitive Landscape
Growing Focus on Product Approvals and Pipeline R&D to Propel Market Growth
The market is partially consolidated and features prominent players like GlaxoSmithKline plc., Sanofi, AstraZeneca, and others. These leading companies are accelerating growth through strategic initiatives such as extensive R&D for pipeline candidates, securing regulatory approvals, launching innovative oral and parenteral therapies, and forming strategic partnerships. Their proactive approach to addressing unmet patient needs continues to fuel the market’s momentum.
Key Industry Development
- September 2023: Boehringer Ingelheim International GmbH received U.S. Food and Drug Administration (FDA) approval for Jardiance (empagliflozin) 10 mg tablets for use in adults with chronic kidney disease (CKD).
- September 2019: Johnson & Johnson Services, Inc. received U.S. FDA approval for its drug INVOKANA (canagliflozin) for the treatment of chronic kidney disease in patients with Type II diabetes.
What’s Driving Japan’s Market? Discover the Latest Chronic Kidney Disease Market Insights
Comments